{
    "root": "30414115-8a10-b828-e063-6294a90ad3ae",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Carbidopa and Levodopa",
    "value": "20250313",
    "ingredients": [
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CARBIDOPA",
            "code": "MNX7R8C5VO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3395"
        },
        {
            "name": "LEVODOPA",
            "code": "46627O600J",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01235"
        }
    ],
    "indications": {
        "text": "carbidopa levodopa extended-release tablets indicated treatment parkinson 's disease , post-encephalitic parkinsonism , symptomatic parkinsonism may follow carbon monoxide intoxication manganese intoxication .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "parkinsonism (DOID:0080855)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080855"
            },
            {
                "text": "symptomatic parkinsonism (DOID:13548)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13548"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carbidopa levodopa extended-release tablet contains carbidopa levodopa 1:4 ratio either 50 mg/200 mg tablet 25 mg/100 mg tablet . daily carbidopa levodopa extended-release tablets must determined careful titration . patients monitored closely dose adjustment period , particularly regard appearance worsening involuntary movements , dyskinesias nausea . carbidopa levodopa extended-release tablets chewed crushed . standard drugs parkinson 's disease , levodopa without decarboxylase inhibitor , may used concomitantly carbidopa levodopa extended-release tablet administered , although may adjusted . since carbidopa prevents reversal levodopa effects caused pyridoxine , carbidopa levodopa extended-release tablets given patients receiving supplemental pyridoxine ( vitamin b 6 ) .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "carbidopa levodopa extended-release tablets 50 mg/200 mg containing 50 mg carbidopa 200 mg levodopa , buff colored , oval , biconvex uncoated tablets debossed \u201c 457 \u201d one side scored side , mottled appearance . supplied follows : unit dose packages 100 ( 10 x 10 ) ndc 68084-282-01 carbidopa levodopa extended-release tablets 25 mg/100 mg containing 25 mg carbidopa 100 mg levodopa , buff colored , oval , biconvex , uncoated tablets debossed \u201c 461 \u201d one side plain side , mottled appearance . supplied follows : unit dose packages 100 ( 10 x 10 ) ndc 68084-281-01 storage store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) . [ usp controlled room temperature ] . store tightly closed container . protected light moisture . protection : blister torn broken .",
    "adverseReactions": "nonselective monoamine oxidase ( mao ) inhibitors contraindicated carbidopa levodopa extended-release tablets . inhibitors must discontinued least two weeks prior initiating therapy carbidopa levodopa extended-release tablets . carbidopa levodopa extended-release tablets may administered concomitantly manufacturer 's recommended dose mao inhibitor selectivity mao type b ( e.g . , selegiline hcl ) ( , ) . carbidopa levodopa extended-release tablets contraindicated patients known hypersensitivity component , patients narrow-angle glaucoma .",
    "indications_original": "Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.",
    "contraindications_original": "Carbidopa and levodopa extended-release tablet contains carbidopa and levodopa in a 1:4 ratio as either the 50 mg/200 mg tablet or the 25 mg/100 mg tablet. The daily dosage of carbidopa and levodopa extended-release tablets must be determined by careful titration. Patients should be monitored closely during the dose adjustment period, particularly with regard to appearance or worsening of involuntary movements, dyskinesias or nausea. Carbidopa and levodopa extended-release tablets should not be chewed or crushed.\n                  Standard drugs for Parkinson's disease, other than levodopa without a decarboxylase inhibitor, may be used concomitantly while carbidopa and levodopa extended-release tablet is being administered, although their dosage may have to be adjusted.\n                  Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, carbidopa and levodopa extended-release tablets can be given to patients receiving supplemental pyridoxine (vitamin B\n  6).",
    "warningsAndPrecautions_original": "Carbidopa and levodopa extended-release tablets 50 mg/200 mg containing 50 mg of carbidopa and 200 mg of levodopa, are buff colored, oval, biconvex uncoated tablets debossed \u201c457\u201d on one side and scored on other side, with mottled appearance. They are supplied as follows:\n  \nUnit dose packages of 100 (10 x 10) NDC 68084-282-01\n \n                  Carbidopa and levodopa extended-release tablets 25 mg/100 mg containing 25 mg carbidopa and 100 mg of levodopa, are buff colored, oval, biconvex, uncoated tablets debossed \u201c461\u201d on one side and plain on other side, with mottled appearance. They are supplied as follows:\n  \nUnit dose packages of 100 (10 x 10) NDC 68084-281-01\n \n                  \n                     Storage\n                     \nStore at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F). [See USP Controlled Room Temperature]. Store in a tightly closed container. Protected from light and moisture.\n \n                  \n                     FOR YOUR PROTECTION: Do not use if blister is torn or broken.",
    "adverseReactions_original": "Nonselective monoamine oxidase\u00a0(MAO) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. These inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release tablets. Carbidopa and levodopa extended-release tablets may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g., selegiline HCl) (See \n       \n \n  \n       \n \n  \n       \n \n  PRECAUTIONS, Drug Interactions).\n      \n\n \n      \n\n \n      \n\n \n                  Carbidopa and levodopa extended-release tablets are contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.",
    "drug": [
        {
            "name": "Carbidopa and Levodopa",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3395"
        }
    ]
}